Literature DB >> 10918427

Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer.

D Avigan1, Z Wu, R Joyce, A Elias, P Richardson, D McDermott, J Levine, L Kennedy, N Giallombardo, D Hurley, J Gong, D Kufe.   

Abstract

The present study examines the nature of humoral and cellular immune reconstitution in 28 patients with advanced breast cancer following high-dose chemotherapy with stem cell rescue. Patients underwent testing of T, B, NK and dendritic cell function at serial time points until 1 year post transplant or until the time of disease progression. Abnormalities in T cell phenotype and function were observed following high-dose chemotherapy that persisted for at least 6-12 months. The vast majority of patients experienced an inversion of the CD4/CD8 ratio and demonstrated an anergic response to candida antigen. Mean T cell proliferation in response to PHA and to co-culture with allogeneic monocytes was significantly compromised. In contrast, mean IgG and IgA levels were normal 6 months post transplant and NK cell yields and function were transiently elevated following high-dose chemotherapy. Dendritic cells generated from peripheral blood progenitors displayed a characteristic phenotype and were potent inducers of allogeneic T cell proliferation in the post-transplant period. The study demonstrates that patients undergoing autologous transplantation for breast cancer experience a prolonged period of T cell dysfunction. In contrast, B, NK, and DC recover more rapidly. These findings carry significant implications for the design of post-transplant immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10918427     DOI: 10.1038/sj.bmt.1702474

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

1.  Monocyte-mediated T-cell suppression and augmented monocyte tryptophan catabolism after human hematopoietic stem-cell transplantation.

Authors:  Ursula Hainz; Petra Obexer; Christiana Winkler; Peter Sedlmayr; Osamu Takikawa; Hildegard Greinix; Anita Lawitschka; Ulrike Pötschger; Dietmar Fuchs; Stephan Ladisch; Andreas Heitger
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

2.  Induction of TGF-beta 1, not regulatory T cells, impairs antiviral immunity in the lung following bone marrow transplant.

Authors:  Stephanie M Coomes; Carol A Wilke; Thomas A Moore; Bethany B Moore
Journal:  J Immunol       Date:  2010-03-26       Impact factor: 5.422

Review 3.  Treatment of breast cancer with chemotherapy in combination with filgrastim: approaches to improving therapeutic outcome.

Authors:  Giuseppe Frasci
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.

Authors:  John H Baird; David J Epstein; John S Tamaresis; Zachary Ehlinger; Jay Y Spiegel; Juliana Craig; Gursharan K Claire; Matthew J Frank; Lori Muffly; Parveen Shiraz; Everett Meyer; Sally Arai; Janice Wes Brown; Laura Johnston; Robert Lowsky; Robert S Negrin; Andrew R Rezvani; Wen-Kai Weng; Theresa Latchford; Bita Sahaf; Crystal L Mackall; David B Miklos; Surbhi Sidana
Journal:  Blood Adv       Date:  2021-01-12

5.  Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution.

Authors:  Nehad M Alajez; Jan Schmielau; Mark D Alter; Michael Cascio; Olivera J Finn
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

6.  Significant impairment in immune recovery after cancer treatment.

Authors:  Duck-Hee Kang; Michael T Weaver; Na-Jin Park; Barbara Smith; Traci McArdle; John Carpenter
Journal:  Nurs Res       Date:  2009 Mar-Apr       Impact factor: 2.381

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.